There are 2867 resources available
1098P - Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
Presenter: Aida Piedra
Session: Poster session 15
826P - Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial
Presenter: Ivan Marquez-Rodas
Session: Poster session 03
1510P - Selective intra-arterial doxorubicin-eluting embolization for desmoid fibromatosis: A combined prospective and retrospective study
Presenter: Eldad Elnekave
Session: Poster session 11
1099P - Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients
Presenter: Francesca Parisi
Session: Poster session 15
827P - An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results
Presenter: Kevin Harrington
Session: Poster session 03
1511P - Efficacy and toxicity of sorafenib in desmoid type fibromatosis: A real-world experience
Presenter: Vikas Garg
Session: Poster session 11
1100P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Feng Li
Session: Poster session 15
828P - Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster session 03
1512P - Pain in patients with desmoid fibromatosis (DF)
Presenter: Nicolas Penel
Session: Poster session 11
1101P - Use of genomic sequencing for the determination of genomic alterations and new therapeutic opportunities in Spanish lung cancer (LC) patients (pts)
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 15